AstraZeneca invests $2bn in cancer drug tie-up with Summit

Summarised from 4 outlets · Updated 29 Sept, 09:43 · Archive

AstraZeneca is investing $2bn in US firm Summit Therapeutics to jointly develop cancer treatments.

AstraZeneca has invested $2bn in US biopharmaceutical company Summit Therapeutics as part of a cancer research collaboration. The two companies will work together to develop and test anti-cancer drugs, combining Summit's experimental medicine with AstraZeneca's treatments.

How it is being reported

• AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-upIndependent Business · 29 Sept, 09:20
• AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-upEvening Standard · 29 Sept, 09:20
• Anthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business liveGuardian Business · 29 Sept, 07:48
• Astrazeneca invests $2bn in cancer drug tie-upCity AM · 29 Sept, 07:36

In this story: AstraZeneca · Summit Therapeutics · United States

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem